These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Results of resection and transplantation for hepatocellular carcinoma in cirrhosis and noncirrhosis. Rayya F; Harms J; Bartels M; Uhlmann D; Hauss J; Fangmann J Transplant Proc; 2008 May; 40(4):933-5. PubMed ID: 18555082 [TBL] [Abstract][Full Text] [Related]
45. Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Soejima Y; Taketomi A; Yoshizumi T; Uchiyama H; Aishima S; Terashi T; Shimada M; Maehara Y Transplantation; 2007 Apr; 83(7):893-9. PubMed ID: 17460559 [TBL] [Abstract][Full Text] [Related]
46. Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis. Bozorgzadeh A; Orloff M; Abt P; Tsoulfas G; Younan D; Kashyap R; Jain A; Mantry P; Maliakkal B; Khorana A; Schwartz S Liver Transpl; 2007 Jun; 13(6):807-13. PubMed ID: 17539001 [TBL] [Abstract][Full Text] [Related]
47. Should we biopsy each liver mass suspicious for HCC before liver transplantation?--no, please don't. Stigliano R; Burroughs AK J Hepatol; 2005 Oct; 43(4):563-8. PubMed ID: 16120469 [No Abstract] [Full Text] [Related]
52. Hepatoblastoma in Explanted Livers of Patients With Biliary Atresia. Amir AZ; Sharma A; Cutz E; Avitzur Y; Shaikh F; Kamath BM; Ling SC; Ghanekar A; Ng VL J Pediatr Gastroenterol Nutr; 2016 Aug; 63(2):188-94. PubMed ID: 27457778 [TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803 [TBL] [Abstract][Full Text] [Related]
54. Liver transplantation for hepatocellular carcinoma after yttrium therapy: a case report. Sotiropoulos GC; Hilgard P; Antoch G; Nowak KM; Ertl J; Fouzas I; Molmenti EP; Sgourakis G; Beckebaum S; Paul A; Broelsch CE; Lang H Transplant Proc; 2008 Dec; 40(10):3804-5. PubMed ID: 19100496 [TBL] [Abstract][Full Text] [Related]
55. [Implications of the immunologic response to the graft in the design of immunosuppressive treatment for liver transplantation]. de la Mata M; Barrera P; Montero JL; Fraga E; Briceño J; Pozo JC; Solórzano G Gastroenterol Hepatol; 2004 Feb; 27 Suppl 1():52-6. PubMed ID: 15195535 [No Abstract] [Full Text] [Related]
57. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in Liver Transplantation. Onaca N; Davis GL; Goldstein RM; Jennings LW; Klintmalm GB Liver Transpl; 2007 Mar; 13(3):391-9. PubMed ID: 17318865 [TBL] [Abstract][Full Text] [Related]
58. An unusual skull lesion in a post-liver transplant patient. Wang C; Chen J; Lu Y; Xia C Liver Int; 2009 Sep; 29(8):1215. PubMed ID: 19490422 [No Abstract] [Full Text] [Related]
59. Expanding transplant criteria for hepatocellular carcinoma: small steps down a long road. Sanchez W Hepatology; 2009 Mar; 49(3):724-5. PubMed ID: 19241486 [No Abstract] [Full Text] [Related]
60. Editorial on "a revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor liver transplantation in hepatocellular carcinoma". Lo CM Surgery; 2007 Jul; 142(1):119-20. PubMed ID: 17630008 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]